Neuphoria Therapeutics Inc.
NEUP · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.16 | 1.30 | -7.28 | -13.75 |
| FCF Yield | 670.23% | -1.18% | -0.20% | -0.16% |
| EV / EBITDA | 52,543.26 | -54.99 | -224.71 | -336.72 |
| Quality | ||||
| ROIC | -0.00% | -111.10% | -122.74% | -52.50% |
| Gross Margin | 95.76% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | -0.21 | 0.95 | 0.68 | 1.00 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -100.00% | – | 83.28% |
| Free Cash Flow Growth | 626.05% | -49.11% | 34.21% | -164.19% |
| Safety | ||||
| Net Debt / EBITDA | 52,586.26 | 0.55 | 0.36 | 0.81 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -1,547.24 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -415,081.10 | -825.20 | -520.83 | 6,129.89 |